NICE Approves Alyftrek, Extending Modulator Treatment to 95% of Cystic Fibrosis Patients

Following the MHRA’s March clearance, NHS England will roll out the once-daily triple therapy to patients aged six or older, including those with rare CF mutations previously excluded.